<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Seven patients with vascular <z:hpo ids='HP_0000726'>dementia</z:hpo> completed an 8-month randomized double-blind crossover trial of <z:chebi fb="0" ids="3181">bromocriptine</z:chebi> in a dosage of up to 30 mg per day </plain></SENT>
<SENT sid="1" pm="."><plain>Patients were assessed using a modified UCLA Parkinson Rating Scale of symptoms and signs, and neuropsychological testing including the Wechsler Adult Intelligence Scale-Revised, Wechsler Memory Scale, modified Thurstone Word Fluency Test, Wisconsin Card Sort, a test of visual vigilance, and a reaction time task </plain></SENT>
<SENT sid="2" pm="."><plain>Subjects failed to perform significantly better on any measure while on <z:chebi fb="0" ids="3181">bromocriptine</z:chebi>, and on several measures their performance while on the drug was worse </plain></SENT>
</text></document>